Related Experiment Video

Updated: Jul 17, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation

Thomas Schmitz1, Evelyne Souil, Roxane Hervé

  • 1Institut National de la Santé et de la Recherche Médicale Unité 767, 4 Avenue de l'Observatoire, 75270 Paris Cedex 06, France.

Journal of Immunology (Baltimore, Md. : 1950)
|January 5, 2007
PubMed

Insights

Phosphodiesterase-4 (PDE4) inhibitors show promise in preventing preterm birth caused by inflammation. By blocking PDE4, these drugs reduce inflammatory responses and protect against pregnancy complications and fetal demise.

Area of Science:

  • Reproductive biology
  • Immunology
  • Pharmacology

Background:

  • Intrauterine inflammation is a primary cause of preterm birth, leading to significant neonatal mortality and morbidity.
  • Preterm delivery is a critical issue in neonatal health, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of phosphodiesterase-4 (PDE4) inhibitors in preventing inflammation-induced preterm delivery.
  • To explore the role of PDE4 activity and expression in the context of intrauterine inflammation.

Main Methods:

  • An in vivo mouse model was used, inducing intrauterine inflammation with Escherichia coli LPS in pregnant mice.
  • PDE4 activity, PDE4B expression, and pro-inflammatory cytokine levels (TNF-alpha, IL-1beta, IL-6, IL-10) were measured.
  • The effect of selective PDE4 inhibition using rolipram on inflammatory markers and pregnancy outcomes was assessed.
  • NF-kappaB translocation was monitored as a marker of cellular activation.

Main Results:

  • Intrauterine LPS injection increased PDE4 activity, PDE4B expression, and pro-inflammatory cytokines, leading to preterm delivery and fetal demise.
  • Selective PDE4 inhibition with rolipram effectively prevented the increase in pro-inflammatory cytokines.
  • PDE4 inhibition disrupted the inflammatory cascade, including NF-kappaB activation, thereby preventing preterm delivery and fetal loss.

Conclusions:

  • PDE4 inhibitors possess anti-inflammatory properties that can prevent inflammation-induced preterm delivery.
  • Targeting PDE4 may offer a novel therapeutic approach to delay preterm birth and improve neonatal outcomes.

More Related Videos

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development08:50

A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development

Published on: June 24, 2020

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...